Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-08
DOI
10.1038/s41598-020-62961-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apatinib as an optional treatment in metastatic colorectal cancer
- (2019) Aiyi Li et al. MEDICINE
- Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO
- (2018) E Dell’Aquila et al. ANNALS OF ONCOLOGY
- A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer
- (2018) Lijun Liang et al. Clinical Colorectal Cancer
- A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
- (2018) Mingming Miao et al. GYNECOLOGIC ONCOLOGY
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
- (2018) Jin Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
- (2018) Miaomiao Gou et al. Scientific Reports
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study
- (2018) Eric Van Cutsem et al. ONCOLOGIST
- Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
- (2018) Xiaoli Liao et al. MEDICINE
- Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
- (2017) Xinyang Liu et al. Journal of Hematology & Oncology
- TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
- (2017) Yasutoshi Kuboki et al. LANCET ONCOLOGY
- Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer
- (2017) Azusa Komori et al. ONCOLOGY
- Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment
- (2017) Ying Lin et al. TUMOR BIOLOGY
- Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
- (2017) Jianping Xu et al. OncoTargets and Therapy
- Salvage treatment with apatinib for advanced non-small-cell lung cancer
- (2017) Zhengbo Song et al. OncoTargets and Therapy
- Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients
- (2017) V. Formica et al. Cancer Biomarkers
- Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors
- (2016) Hai-Qi Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
- (2016) Hyo Jin Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophils in the Tumor Microenvironment
- (2016) Davalyn R. Powell et al. TRENDS IN IMMUNOLOGY
- Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents
- (2016) Marwa A. Aziz et al. Scientific Reports
- Apatinib for the treatment of gastric cancer
- (2016) Giandomenico Roviello et al. Expert Review of Gastroenterology & Hepatology
- Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour
- (2015) J K Pine et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
- (2014) Lorena Rossi et al. ANNALS OF SURGICAL ONCOLOGY
- Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
- (2014) Xichun Hu et al. BMC CANCER
- Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
- (2014) J. Sastre et al. Clinical & Translational Oncology
- Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer
- (2014) James J. Lee et al. Clinical Colorectal Cancer
- Development of a highly-potent anti-angiogenic VEGF8-109heterodimer by directed blocking of its VEGFR-2 binding site
- (2014) Fahimeh Ghavamipour et al. FEBS Journal
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy
- (2014) M. Tampellini et al. TUMOR BIOLOGY
- Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D
- (2013) K. W. Tan et al. BLOOD
- CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
- (2013) Yukiya Narita et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Adverse Events Associated With Antiangiogenic Agents in Combination With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer and Their Management
- (2013) Thomas H. Cartwright Clinical Colorectal Cancer
- Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis
- (2013) Mu-Xing Li et al. INTERNATIONAL JOURNAL OF CANCER
- The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis
- (2013) Alyssa Fischer et al. INVESTIGATIONAL NEW DRUGS
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulation of neutrophil granulocytes in the tumor microenvironment: Mechanisms and consequences for tumor progression
- (2013) Claudia A. Dumitru et al. SEMINARS IN CANCER BIOLOGY
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
- (2012) A. Poprach et al. ANNALS OF ONCOLOGY
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡
- (2012) S. George et al. ANNALS OF ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
- (2012) Manabu Kaneko et al. ONCOLOGY
- A Clinical Study of the Prognostic Factors for Postoperative Early Recurrence in Patients who Underwent Complete Resection for Pulmonary Adenocarcinoma
- (2011) Takehiro Sakai et al. Annals of Thoracic and Cardiovascular Surgery
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
- (2011) W Chua et al. BRITISH JOURNAL OF CANCER
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study
- (2011) Goro Nakayama et al. International Journal of Clinical Oncology
- Neutrophil-Lymphocyte Ratio as a Predictor of Adverse outcomes of Acute Pancreatitis
- (2011) Basem Azab et al. PANCREATOLOGY
- Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
- (2010) Jin Li et al. BMC CANCER
- Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
- (2010) A. Bagri et al. CLINICAL CANCER RESEARCH
- The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy
- (2009) A. S. Strimpakos et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now